NCT04392479View on ClinicalTrials.gov

TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

202

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

June 15, 2023

Study Completion Date

June 30, 2024

Conditions

Cancer ColorectalMetastasis

Interventions

DRUG

Aflibercept-FOLFIRI

DRUG

Aflibercept-mFOLFIRI3

Trial Locations (1)

92300

Franco-British Hospital - GCS IHFB Cognacq-Jay, Levallois-Perret

All Listed Sponsors

collaborator

Fondation ARCAD

OTHER

lead

Hôpital Franco-Britannique-Fondation Cognacq-Jay

OTHER

NCT04392479 - TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. | Biotech Hunter | Biotech Hunter